Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase of over 15% compared to the CSI 300 index in the next six months [12][13]. Core Insights - The company's core products are experiencing rapid growth, particularly the sales of Westgliptin, which saw a year-on-year sales increase of 322.98% and revenue growth of 414.65% in the first three quarters of 2024 [4]. - The company reported a total revenue of 481 million yuan for the first three quarters of 2024, representing a year-on-year increase of 38.02% [3]. - The company has received positive data from the Phase II study of Westgliptin, which showed significant improvements in liver fat and fibrosis indicators [5]. Financial Performance - In Q3 2024, the company achieved a revenue of 179 million yuan, a year-on-year increase of 67.27%, while the net profit attributable to shareholders was a loss of 10 million yuan, a reduction in loss of 78.83% compared to the previous year [3]. - The gross profit margin for the first three quarters of 2024 was 87.58%, with a decrease of 2.41 percentage points year-on-year [6]. - The company’s operating expenses have decreased, with the sales expense ratio dropping by 9.64 percentage points to 49.23% [6]. Product Development - The company’s core product, Westgliptin, has been approved for new indications, which is expected to contribute to revenue growth [4]. - The company is expanding its product portfolio with new indications for Westgliptin, which is anticipated to enhance its market presence [4]. Future Projections - Revenue projections for the company are estimated to be 687 million yuan in 2024, with a growth rate of 31.16% [9]. - The net profit is expected to improve significantly by 2026, with a projected profit of 36 million yuan [9].

Group 1: Company Performance - The company achieved a revenue of 4.81 billion CNY in the first three quarters of 2024, representing a year-on-year growth of 16.73% [1] - Sales of Seglitazone increased by 38.02% year-on-year, while sales of Sidaprim showed a growth of 24.01% [1] - The company reported a revenue increase of 322.98% and a year-on-year growth of 414.65% [1] Group 2: Product Development - CS231295, a new drug for treating tumors, has shown significant preclinical efficacy and is currently under IND acceptance [2] - The company is focusing on developing innovative drugs that meet patient needs and have novel mechanisms of action [1] - The II phase clinical trial for Seglitazone in treating MASH has been selected for a presentation at the 2024 American Liver Meeting, indicating positive preliminary efficacy signals [2] Group 3: Strategic Partnerships and Market Position - The company has established a complete BD team for external cooperation and has maintained effective communication with various industry players [2] - Following the termination of the promotion authorization with Haizheng, the company plans to take over the marketing of Seglitazone in several provinces, enhancing its commercial strategy [3] - The company aims to leverage its own sales team and partnerships for specialized academic promotion of Seglitazone in mainland China [3] Group 4: Clinical Indicators and Regulatory Standards - Insulin resistance is identified as a core pathogenic factor in MASH, with the company focusing on improving clinical indicators related to liver fibrosis [2] - The recognized standard for MASH drug approval is improvement in liver fibrosis, with a focus on non-invasive methods for assessing liver fat [2] - In clinical trials, 51.6% of patients in the Seglitazone 64mg group showed a ≥30% reduction in liver fat after 18 weeks of treatment [2]

证券代码：688321 证券简称：微芯生物 公告编号：2024-080 深圳微芯生物科技股份有限公司 自愿披露关于西奥罗尼胶囊一线治疗广泛期小细胞肺癌获 得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳微芯生物科技股份有限公司（以下简称"公司"）及全资子公司成都微 芯药业有限公司近日收到国家药品监督管理局（以下简称"国家药监局"）签发的 境内生产药品注册临床试验的《药物临床试验批准通知书》，同意公司西奥罗尼 胶囊联合 PD-(L)1 单抗及化疗在广泛期小细胞肺癌一线治疗患者中开展临床试 验。现将相关情况公告如下： 一、药品基本情况 产品名称：西奥罗尼胶囊 受理号：CXHL2400869、CXHL2400870 适应症：联合 PD-(L)1 单抗及化疗一线治疗广泛期小细胞肺癌 申请人：深圳微芯生物科技股份有限公司、成都微芯药业有限公司 二、药品的其他相关情况 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2024 年 8 月 27 日受理的西奥罗尼胶囊符合药品注册的有关要求，同 ...

证券代码：688321 证券简称：微芯生物 公告编号： 2024-079 深圳微芯生物科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2024 年 11 月 18 日(星期一)至 11 月 22 日(星期 五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 ir@chipscreen.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 财务总监：黎建勋先生 独立董事：罗勇根博士、黄民博士、王艳梅博士 深圳微芯生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 31 日发布公司 2024 年第三季度报告，为便于广大投资者更全 面深入地了解公司 2024 年三季度的经营成果、研发进展，公司计划 于 2024 年 11 月 25 日上午 10:00-11:00 举行 2024 年第三季度业绩 说明会，就投资者关心的问题进行交流。 一、 说明会类型 会议召开时间：2024 年 1 ...

证券代码：688321 证券简称：微芯生物 公告编号：2024-078 深圳微芯生物科技股份有限公司 第三届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 深圳微芯生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 30 日 以通讯方式召开了第三届监事会第五次会议（以下简称"本次会议"）。本次的会 议通知于 2024 年 10 月 23 日通过电子邮件方式送达全体监事。会议应出席监事 3 人，实际出席监事 3 人，会议由公司监事会主席何杰先生主持。本次会议的召 集、召开程序和方式符合《公司法》等法律法规以及《公司章程》的有关规定， 会议决议合法、有效。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 1 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《2024 年第三季度报告》。 （二）审议通过《关于使用自有资金进行现金管理的议案》 为提高公司自有资金使用效率和收益，同意公司在保证不影响公司资金使用 和投资计划正常进行的前提 ...

深圳微芯生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 30 日 以现场及通讯相结合的方式召开第三届董事会第七次会议（以下简称"本次会 议"）。本次的会议通知于 2024 年 10 月 23 日通过电子邮件方式送达全体董事。 会议应出席董事 8 人，实际到会董事 8 人，会议由公司董事长 XIANPING LU 先生 主持。会议的召集和召开程序符合《公司法》等法律法规以及《公司章程》的有 关规定，会议决议合法、有效。 二、董事会会议审议情况 证券代码：688321 证券简称：微芯生物 公告编号：2024-077 深圳微芯生物科技股份有限公司 第三届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 本议案已经董事会审计委员会审议通过，并同意提交董事会审议。 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《2024 年第三季度报告》。 1 （二）审议通过《关于与海正药业签订<独占许可及联合营销战略合作协议 之终止协议>的议案》 同意 ...

证券代码：688321 证券简称：微芯生物 公告编号：2024-076 深圳微芯生物科技股份有限公司 关于与海正药业提前终止推广合作的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 原协议及终止协议主要内容： 随着公司西格列他钠片于2022年成功纳入国家医保目录以及公司自身销售 团队逐步成熟，为更好地落实公司协议产品下一发展阶段的产品商业化推广策略， 积极应对未来的市场竞争格局，经双方友好协商，并经公司第三届董事会第七次 会议审议通过，公司拟与海正药业签署《独占许可及联合营销战略合作协议之终 止协议》（以下简称"终止协议"），原协议自2024年10月31日（以下简称"终 止日"）起终止，公司收回原协议约定的西格列他钠片在河南、浙江、江苏等19 个省份的独家市场推广权。公司销售团队将负责西格列他钠片在中国大陆地区的 全部推广活动。 按照《公司章程》等相关法律法规规定，本次终止独占许可及联合营销战略 合作协议已经公司第三届董事会第七次会议审议通过，公司与海正药业不存在关 联关系，亦不构成关联交易，无需提交 ...

Financial Performance - Operating revenue for Q3 2024 was ¥178,954,534.61, an increase of 67.27% compared to the same period last year[2] - Net profit attributable to shareholders was -¥10,078,540.92, with a year-to-date loss of -¥51,084,939.83, representing a decrease of 147.26% year-on-year[2] - Basic and diluted earnings per share for the year-to-date period were both -¥0.1252, reflecting a decrease of 147.26% year-on-year[2] - The net profit for Q3 2024 was -51,084,939.83 RMB, compared to a profit of 68,432,323.32 RMB in Q3 2023, representing a significant decline[18] - The total comprehensive income for Q3 2024 was -51,588,378.16 RMB, down from 70,373,533.42 RMB in the same period last year[19] - Basic and diluted earnings per share for Q3 2024 were both -0.1252 RMB, compared to 0.2649 RMB in Q3 2023[19] Cash Flow - Cash flow from operating activities for Q3 2024 was ¥59,016,488.83, a significant increase of 530.08% compared to the same period last year[2] - Cash flow from operating activities for the first three quarters of 2024 was 74,564,294.54 RMB, a recovery from -112,013,154.32 RMB in the same period last year[22] - Cash inflow from investment activities in Q3 2024 was 1,106,464,509.65 RMB, compared to 750,839,196.43 RMB in Q3 2023[22] - Cash outflow from investment activities totaled 1,386,493,392.38 RMB in Q3 2024, compared to 1,135,517,773.31 RMB in Q3 2023[22] - Cash flow from financing activities in Q3 2024 was 132,141,925.49 RMB, down from 339,051,069.70 RMB in Q3 2023[22] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥3,338,141,167.42, an increase of 4.21% from the end of the previous year[3] - The company's total assets increased to CNY 3,338,141,167.42, compared to CNY 3,203,249,429.12 at the end of the previous year, reflecting a growth of about 4.2%[15] - The total liabilities of the company rose to CNY 1,694,830,204.04 from CNY 1,493,353,557.17, which is an increase of about 13.5%[15] - The company's cash and cash equivalents decreased to CNY 134,282,130.33 from CNY 216,717,350.00, representing a decline of approximately 38.2%[14] - Inventory levels increased slightly to CNY 49,417,728.34 from CNY 47,129,293.63, showing a growth of about 4.8%[14] - The total equity attributable to shareholders decreased to CNY 1,643,310,963.38 from CNY 1,709,895,871.95, reflecting a decline of approximately 3.9%[16] - Short-term borrowings decreased significantly to CNY 71,161,547.64 from CNY 130,112,786.24, indicating a reduction of about 45.3%[15] Research and Development - R&D expenses totaled ¥65,497,591.41, a decrease of 11.08% year-on-year, representing 36.60% of operating revenue, down 32.25 percentage points[3] - Research and development expenses for the first three quarters of 2024 were CNY 147,574,384.70, down from CNY 211,230,689.78 in the previous year, indicating a decrease of approximately 30.2%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,601[9] - The largest shareholder, BGI Group, holds 34,705,162 shares, representing 8.51% of total shares[9] - The second-largest shareholder, Shenzhen Haiyue Men Biotechnology Development Co., Ltd., holds 22,936,008 shares, representing 5.62%[9] - The company had a total of 15,285,290 shares held by Shenzhen Haide Kangcheng Investment Partnership, representing 3.75% of total shares[12] - The company had no outstanding shares borrowed for margin trading at the end of the reporting period[11] - The company has a consistent shareholder structure with several entities having a unified action relationship[10] - The company had no changes in the number of shares held by major shareholders due to margin trading activities[12] Financial Reporting - The company’s financial statements are unaudited for the reporting period[13] - The company’s total assets and liabilities will be detailed in the upcoming financial reports[13] - Shenzhen Micu Biotechnology Co., Ltd. will implement new accounting standards starting in 2024, affecting the financial statements from the beginning of the year[23] - The company reported its Q3 2024 financial results on October 31, 2024[23] - The board of directors announced the adjustments related to the first-time execution of the new accounting standards[23] - No specific performance metrics or user data were disclosed in the report[23] - Future outlook and performance guidance were not provided in the document[23] - There were no mentions of new product or technology developments in the report[23] - Market expansion and acquisition strategies were not discussed in the content[23] - Other new strategies were not highlighted in the financial report[23] - The document does not contain specific financial figures or percentages related to performance[23] - The report is classified as not applicable for the new accounting standards implementation[23]

| 证券代码：688321 | 证券简称：微芯生物 公告编号： 2024-075 | | --- | --- | | 转债代码：118012 | 转债简称：微芯转债 | 深圳微芯生物科技股份有限公司 关于不向下修正"微芯转债"转股价格的公告 重要内容提示： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ●截至 2024 年 10 月 18 日，公司股票已出现连续三十个交易日中至少有十 五个交易日的收盘价格低于当期转股价格的 85%的情形，已触发"微芯转债" 转股价格的向下修正条款。 ●经深圳微芯生物科技股份有限公司（以下简称"公司"）第三届董事会第 六次会议决定，本次不向下修正"微芯转债"转股价格。同时在未来六个月内 （即 2024 年 10 月 19 日起至 2025 年 4 月 18 日），如果再次触发"微芯转债" 转股价格向下修正条件，亦不提出向下修正方案。 一、可转债发行上市情况 经中国证券监督管理委员会"证监许可[2022]1234 号"文同意注册，公司 于 2022 年 7 月 5 日向不特定对象发行可转换公 ...

证券代码：688321 证券简称：微芯生物 公告编号：2024-074 深圳微芯生物科技股份有限公司 自愿披露关于 CS231295 片临床试验申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳微芯生物科技股份有限公司（以下简称"公司"）及全资子公司深圳微 芯药业有限责任公司近日收到国家药品监督管理局（以下简称"国家药监局"）签 发的境内生产药品注册临床试验的《受理通知书》，CS231295 片治疗晚期实体瘤 的临床试验申请获得受理。 本次申请为新药临床试验申请，在临床试验申请获得受理后，自受理之日起 60 日内未收到药审中心否定或质疑意见的，公司便可以按照提交的方案开展临 床试验。临床试验能否最终开展存在不确定性，敬请广大投资者注意防范投资风 险，谨慎决策。现将相关情况公告如下： 一、药品基本情况 1、产品名称：CS231295 片 受理号：CXHL2401105（1 mg）、CXHL2401107（5mg）、CXHL2401108（10mg） 适应症：晚期实体瘤 2024 年 10 ...